"Designing Growth Strategies is in our DNA"

Transforming Growth Factor Beta (Tgf-Beta) Inhibitor – Pipeline Review, 2020

Region : Global | Report ID: FBI100903

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Table of Content:

  1. Introduction
    1. Report Overview
  2. TGF-Beta Inhibitor  - Overview
  3. Executive Summary
  4. TGF-Beta Inhibitor  : Pipeline Assessment
    1. By Stage of Development
    2. By Route of Administration
    3. By Drug Class
    4. By Molecule Type
    5. By Therapy Area / Indication
    6. By Drug Target
    7. By Sponsor
  5. TGF-Beta Inhibitor : Company & Drug Profiles
    1. Clinical Stage
      1. AVID200 – Forbius (Formation Biologics)
        1. Company Overview
        2. Product Description
        3. R&D Status & Development Activities
        4. Mechanism of Action
        5. Molecule Type
        6. Stage of Development
        7. Indications
        8. Route of Administration
        9. Funding
      2. Galunisertib – Eli Lilly and Company
        1. Company Overview
        2. Product Description
        3. R&D Status & Development Activities
        4. Mechanism of Action
        5. Molecule Type
        6. Stage of Development
        7. Indications
        8. Route of Administration
        9. Funding
      3. TEW-7197 – MedPacto, Inc.
        1. Company Overview
        2. Product Description
        3. R&D Status & Development Activities
        4. Mechanism of Action
        5. Molecule Type
        6. Stage of Development
        7. Indications
        8. Route of Administration
        9. Funding
      4. Others
    2. Preclinical
      1. Company Overview
      2. Product Description
      3. R&D Status & Development Activities
      4. Mechanism of Action
      5. Molecule Type
      6. Indications
      7. Route of Administration
      8. Funding
  6. TGF-Beta Inhibitor : An Overview on Dormant & Discontinued Pipeline Candidates
    1. Overview
    2. Product Description
    3. Reason for Discontinuation
  7. TGF-Beta Inhibitor : Additional Key Insights
    1. TGF-Beta Inhibitor Applications in Oncology
  8. TGF-Beta Inhibitor: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.

Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann